Professor Philippe Clézardin

BSc, MSc, PhD, DSc

School of Medicine and Population Health

Honorary Professor of Bone Oncology

Philippe Clezardin
Profile picture of Philippe Clezardin
p.clezardin@sheffield.ac.uk
EU28, E Floor, The Medical School

Full contact details

Professor Philippe Clézardin
School of Medicine and Population Health
EU28, E Floor
The Medical School
Beech Hill Road
Sheffield
S10 2RX
Profile

For enquiries please contact - SMPH-West-Operational@sheffield.ac.uk

I was awarded my PhD from the University of Lyon, France, in 1984 after which I joined the Medical Research Council / Scottish National Blood Transfusion Centre in Edinburgh as a post-doctoral research associate for 2 years. I was appointed in 1987 as Research Scientist (Lecturer) at INSERM (National Institute for Health and Medical Research), Lyon, France. In 1990 I undertook a one-year sabbatical as visiting scientist at the Ottawa General Hospital (Ottawa, Canada). In 1991 I was appointed Senior Research Scientist (Senior Lecturer) and in 1993 Research Director 2nd class (Reader) at INSERM. In 2005 I was appointed Research Director 1st Class (Professor) and became head of the INSERM Research Unit UMR_S664 entitled: “Mechanisms and Treatments of Bone Metastases” (2005-2010) and then Director of the Federative Research Institute “IFR62” entitled: “Cancer, Nutrition and Metabolism” (14 laboratories, circa: 500 people; 2007-2010). From 2011, I am head of the INSERM Research Unit UMR_S1033 entitled: “Pathophysiology, Diagnosis and Treatments of Bone Diseases” (). I have recently become an Honorary Professor of Bone Oncology.

Research interests

My main research interest is the understanding of molecular mechanisms that govern breast cancer cell colonisation of the bone marrow, with the goal of developing novel biomarkers to identify patients at high risk for developing bone metastasis.

Current projects:

ROBO. Role of axon guidance, roundabout (ROBO) transmembrane receptors in breast cancer bone metastasis formation.

LOXs. Role of lysyl oxidases in early onset of breast cancer bone metastasis formation.

AMG161. Anti-tumour effect of a human anti-RANKL monoclonal antibody on early-stage bone colonisation of human RANK-expressing breast cancer cells

MicroRNAs. Role of breast cancer stem cell-derived microRNAs, and their mRNA/protein targets in controlling bone metastasis formation.

Publications

Show: Featured publications All publications

Journal articles

  • Pantano F, Croset M, Driouch K, Bednarz-Knoll N, Iuliani M, Ribelli G, Bonnelye E, Wikman H, Geraci S, Bonin F , Simonetti S et al (2021) . Oncogene.
  • Clezardin P, Coleman R, Puppo M, Ottewell P, Bonnelye E, Paycha F, Confavreux CB & Holen I (2020) . Physiological Reviews.
  • Puppo M, Taipaleenmäki H, Hesse E & Clézardin P (2019) . British Journal of Pharmacology.
  • Vargas G, Bouchet M, Bouazza L, Reboul P, Boyault C, Gervais M, Kan C, Benetollo C, Brevet M, Croset M , Mazel M et al (2019) . Oncogene, 38(7), 950-964.
  • Croset M, Pantano F, Kan CWS, Bonnelye E, Descotes F, Alix-Panabières C, Lecellier C-H, Bachelier R, Allioli N, Hong S-S , Bartkowiak K et al (2018) . Cancer Research, 78(18), 5259-5273.
  • Sousa S & Clézardin P (2018) . Calcified Tissue International, 102(2), 227-250.
  • Reynaud C, Ferreras L, Di Mauro P, Kan C, Croset M, Bonnelye E, Pez F, Thomas C, Aimond G, Karnoub AE , Brevet M et al (2017) . Cancer Research, 77(2), 268-278.
  • Hadji P, Coleman RE, Wilson C, Powles TJ, Clézardin P, Aapro M, Costa L, Body J-J, Markopoulos C, Santini D , Diel I et al (2016) . Annals of Oncology, 27(3), 379-390.
  • Sahay D, Leblanc R, Grunewald TGP, Ambatipudi S, Ribeiro J, Clézardin P & Peyruchaud O (2015) . Oncotarget, 6(24), 20604-20620.
  • Croset M, Goehrig D, Frackowiak A, Bonnelye E, Ansieau S, Puisieux A & Clézardin P (2014) . Journal of Bone and Mineral Research, 29(8), 1886-1899.
  • Benzaïd I, Mönkkönen H, Bonnelye E, Mönkkönen J & Clézardin P (2012) . Clinical Cancer Research, 18(22), 6249-6259.
  • Coleman R, Gnant M, Morgan G & Clezardin P (2012) . JNCI Journal of the National Cancer Institute, 104(14), 1059-1067.
  • Fradet A, Sorel H, Bouazza L, Goehrig D, Dépalle B, Bellahcène A, Castronovo V, Follet H, Descotes F, Aubin JE , Clézardin P et al (2011) . Cancer Research, 71(17), 5728-5738.
  • Benzaïd I, Mönkkönen H, Stresing V, Bonnelye E, Green J, Mönkkönen J, Touraine J-L & Clézardin P (2011) . Cancer Research, 71(13), 4562-4572.
  • Le Gall C, Bellahcène A, Bonnelye E, Gasser JA, Castronovo V, Green J, Zimmermann J & Clézardin P (2007) . Cancer Research, 67(20), 9894-9902.
  • Zhao Y, Bachelier R, Treilleux I, Pujuguet P, Peyruchaud O, Baron R, Clément-Lacroix P & Clézardin P (2007) . Cancer Research, 67(12), 5821-5830.

All publications

Journal articles

  • Massy E, Rousseau JC, Gueye M, Bonnelye E, Brevet M, Chambard L, Duruisseaux M, Borel O, Roger C, Guelminger R , Pialat JB et al (2021) . Journal of Bone Oncology, 29, 100364-100364.
  • Puppo M, Valluru MK & Clézardin P (2021) . Current Osteoporosis Reports.
  • Pantano F, Croset M, Driouch K, Bednarz-Knoll N, Iuliani M, Ribelli G, Bonnelye E, Wikman H, Geraci S, Bonin F , Simonetti S et al (2021) . Oncogene.
  • Clezardin P, Coleman R, Puppo M, Ottewell P, Bonnelye E, Paycha F, Confavreux CB & Holen I (2020) . Physiological Reviews.
  • Gardegaront M, Plet G, Delpuech B, Bouazza L, Brevet M, Pialat J-B, Clézardin P, Confavreux CB, Mitton D & Follet H (2020) . Computer Methods in Biomechanics and Biomedical Engineering, 23(sup1), S115-S116.
  • Bouchet M, Lainé A, Boyault C, Proponnet-Guerault M, Meugnier E, Bouazza L, Kan CWS, Geraci S, El-Moghrabi S, Hernandez-Vargas H , Benetollo C et al (2020) . Cancer Research.
  • Das S, Clézardin P, Kamel S, Brazier M & Mentaverri R (2020) . Frontiers in Oncology, 10(1).
  • Dewulf J, Vangestel C, Verhoeven Y, van Dam P, Elvas F, Van den Wyngaert T & Clézardin P (2019) . The Quarterly Journal of Nuclear Medicine and Molecular Imaging, 63(2), 98-111.
  • Puppo M, Taipaleenmäki H, Hesse E & Clézardin P (2019) . British Journal of Pharmacology.
  • Peters S, Clézardin P, Márquez-Rodas I, Niepel D & Gedye C (2019) . Clinical and Translational Oncology, 21(8), 977-991.
  • Vargas G, Bouchet M, Bouazza L, Reboul P, Boyault C, Gervais M, Kan C, Benetollo C, Brevet M, Croset M , Mazel M et al (2019) . Oncogene, 38(7), 950-964.
  • Delliaux C, Tian TV, Bouchet M, Fradet A, Vanpouille N, Flourens A, Deplus R, Villers A, Leroy X, Clézardin P , de Launoit Y et al (2018) . Cancer Letters, 438, 32-43.
  • Lelièvre L, Clézardin P, Magaud L, Roche L, Tubiana-Mathieu N, Tigaud J-D, Topart D, Raban N, Mouret-Reynier M-A & Mathevet P (2018) . Clinical Breast Cancer, 18(6), e1311-e1321.
  • Gineyts E, Bonnet N, Bertholon C, Millet M, Pagnon-Minot A, Borel O, Geraci S, Bonnelye E, Croset M, Suhail A , Truica C et al (2018) . Calcified Tissue International, 103(5), 567-580.
  • Croset M, Pantano F, Kan CWS, Bonnelye E, Descotes F, Alix-Panabières C, Lecellier C-H, Bachelier R, Allioli N, Hong S-S , Bartkowiak K et al (2018) . Cancer Research, 78(18), 5259-5273.
  • Kassem L, Clézardin P & Treilleux I (2018) . Annals of Oncology, 29, vi31-vi31.
  • Chambard L, Girard N, Ollier E, Rousseau J-C, Duboeuf F, Carlier M-C, Brevet M, Szulc P, Pialat J-B, Wegrzyn J , Clezardin P et al (2018) . Bone, 108, 202-209.
  • Sousa S & Clézardin P (2018) . Calcified Tissue International, 102(2), 227-250.
  • Clézardin P (2017) . Joint Bone Spine, 84(6), 677-684.
  • Delpuech B, Confavreux C, Bouazza L, Geraci S, Clezardin P, Mitton D & Follet H (2017) . Computer Methods in Biomechanics and Biomedical Engineering, 20(sup1), S57-S58.
  • Boudot C, Hénaut L, Thiem U, Geraci S, Galante M, Saldanha P, Saidak Z, Six I, Clézardin P, Kamel S & Mentaverri R (2017) . Oncotarget, 8(34).
  • Fowlkes B, Ghanouni P, Sanghvi N, Coussios C, Lyon PC, Gray M, Mannaris C, Victor MDS, Stride E, Cleveland R , Carlisle R et al (2017) . Journal of Therapeutic Ultrasound, 5(S1).
  • Clézardin P (2017) . Revue du Rhumatisme Monographies, 84(2), 107-114.
  • Reynaud C, Ferreras L, Di Mauro P, Kan C, Croset M, Bonnelye E, Pez F, Thomas C, Aimond G, Karnoub AE , Brevet M et al (2017) . Cancer Research, 77(2), 268-278.
  • Fradet A, Bouchet M, Delliaux C, Gervais M, Kan C, Benetollo C, Pantano F, Vargas G, Bouazza L, Croset M , Bala Y et al (2016) . Oncotarget, 7(47), 77071-77086.
  • Kan C, Vargas G, Pape F & Clézardin P (2016) . International Journal of Molecular Sciences, 17(10).
  • Le Pape F, Vargas G & Clézardin P (2016) . Journal of Bone Oncology, 5(3), 93-95.
  • Pantano F, Croset M, Driouch K, Iuliani M, Fioramonti M, Santini D, Tonini G, Bednarz-Knoll N, Pantel K & Clézardin P (2016) . Annals of Oncology, 27, iv60-iv60.
  • Lafond M, Mestas J-L, Prieur F, Chettab K, Geraci S, Clézardin P & Lafon C (2016) . Ultrasound in Medicine & Biology, 42(1), 220-231.
  • Hadji P, Coleman RE, Wilson C, Powles TJ, Clézardin P, Aapro M, Costa L, Body J-J, Markopoulos C, Santini D , Diel I et al (2016) . Annals of Oncology, 27(3), 379-390.
  • Tardoski S, Gineyts E, Ngo J, Kocot A, Clézardin P & Melodelima D (2015) . Ultrasound in Medicine & Biology, 41(10), 2740-2754.
  • Clément-Demange L & Clézardin P (2015) . Current Opinion in Pharmacology, 22, 79-86.
  • Sahay D, Leblanc R, Grunewald TGP, Ambatipudi S, Ribeiro J, Clézardin P & Peyruchaud O (2015) . Oncotarget, 6(24), 20604-20620.
  • Clézardin P (2015) . Oncologie, 17(3), 69-74.
  • Arkko S, Zlatev HP, Mönkkönen H, Räikkönen J, Benzaïd I, Clézardin P, Mönkkönen J & Määttä JA (2015) . Cancer Letters, 357(1), 279-285.
  • Richert L, Keller L, Wagner Q, Bornert F, Gros C, Bahi S, Clauss F, Bacon W, Clézardin P, Benkirane-Jessel N & Fioretti F (2015) . World Journal of Nano Science and Engineering, 05(04), 219-228.
  • Croset M, Kan C & Clézardin P (2015) . BoneKEy Reports, 4.
  • Tardoski S, Ngo J, Gineyts E, Roux J-P, Clézardin P & Melodelima D (2015) . Scientific Reports, 5(1).
  • Terpos E, Confavreux CB & Clézardin P (2015) . BoneKEy Reports, 4.
  • Amoroso V, Petrelli F, Pedersini R, Simoncini EL, Clézardin P, Barni S & Berruti A (2015) . Future Oncology, 11(21), 2853-2856.
  • Sahay D, Leblanc R, Ribeiro J, Clezardin P & Peyruchaud O (2014) . European Journal of Cancer, 50, 182-182.
  • Leblanc R, Lee S-C, David M, Bordet J-C, Norman DD, Patil R, Miller D, Sahay D, Ribeiro J, Clézardin P , Tigyi GJ et al (2014) . Blood, 124(20), 3141-3150.
  • Raphaël M, Lehen’kyi V, Vandenberghe M, Beck B, Khalimonchyk S, Vanden Abeele F, Farsetti L, Germain E, Bokhobza A, Mihalache A , Gosset P et al (2014) . Proceedings of the National Academy of Sciences, 111(37), E3870-E3879.
  • Bachelier R, Confavreux CB, Peyruchaud O, Croset M, Goehrig D, van der Pluijm G & Clézardin P (2014) . International Journal of Cancer, 135(6), 1319-1329.
  • Croset M, Goehrig D, Frackowiak A, Bonnelye E, Ansieau S, Puisieux A & Clézardin P (2014) . Journal of Bone and Mineral Research, 29(8), 1886-1899.
  • David M, Machuca-Gayet I, Kikuta J, Ottewell P, Mima F, Leblanc R, Bonnelye E, Ribeiro J, Holen I, Vales RL , Jurdic P et al (2014) . Journal of Biological Chemistry, 289(10), 6551-6564.
  • Girard N, Confavreux CB, Pialat JB, Devouassoux M, Clézardin P, Isaac S, Thivolet-Béjui F, Bringuier PP & Brevet M (2014) . Revue des Maladies Respiratoires, 31, A131-A131.
  • Confavreux CB, Girard N, Pialat J-B, Bringuier P-P, Devouassoux-Shisheboran M, Rousseau J-C, Isaac S, Thivolet-Bejui F, Clezardin P & Brevet M (2014) . BoneKEy Reports, 3.
  • Vieillard MH, Chiras J, Clézardin P, Ferrero J-M, Barrière J & Beuzeboc P (2013) . Oncologie, 15(12), 673-686.
  • Ricci E, Mattei E, Dumontet C, Eaton CL, Hamdy F, van der Pluije G, Cecchini M, Thalmann G, Clezardin P & Colombel M (2013) . The Prostate, 73(16), 1738-1746.
  • Clézardin P (2013) . Bulletin du Cancer, 100(11), 1083-1091.
  • Santana-Codina N, Carretero R, Sanz-Pamplona R, Cabrera T, Guney E, Oliva B, Clezardin P, Olarte OE, Loza-Alvarez P, Méndez-Lucas A , Perales JC et al (2013) . Molecular & Cellular Proteomics, 12(8), 2111-2125.
  • Stresing V, Baltziskueta E, Rubio N, Blanco J, Arriba MC, Valls J, Janier M, Clézardin P, Sanz-Pamplona R, Nieva C , Marro M et al (2013) . Oncogene, 32(6), 804-804.
  • Stresing V, Baltziskueta E, Rubio N, Blanco J, Arriba M, Valls J, Janier M, Clézardin P, Sanz-Pamplona R, Nieva C , Marro M et al (2013) . Oncogene, 32(6), 724-735.
  • Clézardin P (2013) . BoneKEy Reports, 2.
  • Thiem U, Boudot C, Lopez I, Hénaut L, Clézardin P, Kamel S & Mentaverri R (2012) . Bone, 51(6), S28-S29.
  • Kischel P, Bellahcene A, Deux B, Lamour V, Dobson R, De Pauw E, Clezardin P & Castronovo V (2012) Overexpression of CD9 in human breast cancer cells promotes the development of bone metastases. Anticancer Research, 32(12), 5211-5220.
  • Pantano F, Clézardin P & Santini D (2012) . Journal of Bone Oncology, 1(3), 67-68.
  • Benzaïd I, Mönkkönen H, Bonnelye E, Mönkkönen J & Clézardin P (2012) . Clinical Cancer Research, 18(22), 6249-6259.
  • Clezardin P (2012) . Clinical Cancer Research, 18(21), 6077-6077.
  • Thariat J, Leysalle A, Vignot S, Marcy P-Y, Lacout A, Bera G, Lagrange J-L, Clezardin P & Chiras J (2012) . 䲹Գ/鲹徱dzٳé辱, 16(5-6), 330-338.
  • Gnant M & Clézardin P (2012) . Cancer Treatment Reviews, 38(5), 407-415.
  • Coleman R, Gnant M, Morgan G & Clezardin P (2012) . JNCI Journal of the National Cancer Institute, 104(14), 1059-1067.
  • Gibert B, Eckel B, Gonin V, Goldschneider D, Fombonne J, Deux B, Mehlen P, Arrigo A-P, Clézardin P & Diaz-Latoud C (2012) . British Journal of Cancer, 107(1), 63-70.
  • Dumont B, Castronovo V, Peulen O, Blétard N, Clézardin P, Delvenne P, De Pauw EA, Turtoi A & Bellahcène A (2012) . Journal of Proteome Research, 11(4), 2247-2260.
  • DAVID M, RIBEIRO J, DESCOTES F, SERRE C-M, BARBIER M, MURONE M, CLÉZARDIN P & PEYRUCHAUD O (2012) . International Journal of Oncology, 40(4), 1133-1141.
  • Clezardin P (2012) . Anti-Cancer Agents in Medicinal Chemistry, 12(2), 102-113.
  • Clézardin P (2012) . Oncologie, 14(1), 31-36.
  • Colombel M, Eaton CL, Hamdy F, Ricci E, van der Pluijm G, Cecchini M, Mege-Lechevallier F, Clezardin P & Thalmann G (2012) . The Prostate, 72(7), 713-720.
  • Ferrari S, Seeman E, Clézardin P, Karasik D, Little DG & Matsumoto T (2011) . IBMS BoneKEy, 8(11), 305-312.
  • Ferrari S, Seeman E, Clézardin P, Karasik D, Little DG & Matsumoto T (2011) . IBMS BoneKEy, 8(10), 428-432.
  • Benzaïd I, Mönkkönen H & Clézardin P (2011) . European Journal of Cancer, 47, S117-S117.
  • Croset M, Bachelier R, Allioli N, Hong SS, Aqami R & Clezardin P (2011) . European Journal of Cancer, 47, S332-S332.
  • Ferrari S, Seeman E, Clézardin P, Karasik D, Little DG & Matsumoto T (2011) . IBMS BoneKEy, 8(9), 390-396.
  • Fradet A, Sorel H, Bouazza L, Goehrig D, Dépalle B, Bellahcène A, Castronovo V, Follet H, Descotes F, Aubin JE , Clézardin P et al (2011) . Cancer Research, 71(17), 5728-5738.
  • Ferrari S, Seeman E, Clézardin P, Karasik D, Little DG & Matsumoto T (2011) . IBMS BoneKEy, 8(8), 352-361.
  • Ferrari S, Seeman E, Clézardin P, Karasik D, Little DG & Matsumoto T (2011) . IBMS BoneKEy, 8(7), 305-312.
  • Benzaïd I, Mönkkönen H, Stresing V, Bonnelye E, Green J, Mönkkönen J, Touraine J-L & Clézardin P (2011) . Cancer Research, 71(13), 4562-4572.
  • Clézardin P (2011) . Bulletin du Cancer, 98(7), 837-846.
  • Ferrari S, Seeman E, Clézardin P, Karasik D, Little DG & Matsumoto T (2011) . IBMS BoneKEy, 8(6), 257-263.
  • Ferrari S, Seeman E, Clézardin P, Karasik D, Little DG & Matsumoto T (2011) . IBMS BoneKEy, 8(5), 211-220.
  • Clézardin P (2011) . Breast Cancer Research, 13(2).
  • Ferrari S, Seeman E, Clézardin P, Karasik D, Little DG & Matsumoto T (2011) . IBMS BoneKEy, 8(4), 171-177.
  • Ricci E, Bourrelie E, Martin X, Dumontet C, Clezardin P, Thalmann G & Colombel M (2011) . European Urology Supplements, 10(2), 265-265.
  • Clézardin P (2011) . IBMS BoneKEy, 8(3), 159-164.
  • Ferrari S, Seeman E, Clézardin P, Karasik D, Little DG & Matsumoto T (2011) . IBMS BoneKEy, 8(3), 128-134.
  • Contié S, Voorzanger-Rousselot N, Litvin J, Clézardin P & Garnero P (2011) . Bone, 48(3), 672-672.
  • Pez F, Dayan F, Durivault J, Kaniewski B, Aimond G, Le Provost GS, Deux B, Clézardin P, Sommer P, Pouysségur J & Reynaud C (2011) . Cancer Research, 71(5), 1647-1657.
  • Ferrari S, Seeman E, Clézardin P, Karasik D, Little DG & Matsumoto T (2011) . IBMS BoneKEy, 8(2), 65-73.
  • Stresing V, Fournier PG, Bellahcène A, Benzaïd I, Mönkkönen H, Colombel M, Ebetino FH, Castronovo V & Clézardin P (2011) . Bone, 48(2), 259-266.
  • Benzaid* I, Monkkonen H, Stresing V, Bonnelye E, Green J, Monkkonen J & Clézardin P (2011) . Bone, 48(1), S46-S46.
  • David M, Leblanc R, Deux B, Serre CM, Ribeiro J, Clézardin P & Peyruchaud* O (2011) . Bone, 48(1), S39-S40.
  • Croset* M, Goëhrig D, Bonnelye E, Ansieau S, Puisieux A & Clézardin P (2011) . Bone, 48(1), S47-S48.
  • Contié S, Voorzanger-Rousselot N, Litvin J, Clézardin P & Garnero P (2011) . International Journal of Cancer, 128(2), 352-360.
  • Clézardin P (2011) . Bone, 48(1), 71-79.
  • Clézardin P, Benzaïd I & Croucher PI (2011) . Bone, 49(1), 66-70.
  • Contié S, Voorzanger-Rousselot N, Litvin J, Bonnet N, Ferrari S, Clézardin P & Garnero P (2010) . Calcified Tissue International, 87(4), 341-350.
  • Clézardin P (2010) . Bulletin du Cancer, 97(8), 937-949.
  • Fournier PG, Stresing V, Ebetino FH & Clezardin P (2010) . Neoplasia, 12(7), 571-578.
  • Benzaid I & Clézardin P (2010) . IBMS BoneKEy, 7(6), 208-217.
  • Pez F, Dayan F, Durivault J, Kaniewski B, Aimond G, Deux B, Clezardin P, Sommer P, Pouysségur J & Reynaud C (2010) . European Journal of Cancer Supplements, 8(5), 135-136.
  • Green J & Clézardin P (2010) . Seminars in Oncology, 37, S3-S11.
  • Coleman RE, Lipton A, Roodman GD, Guise TA, Boyce BF, Brufsky AM, Clézardin P, Croucher PI, Gralow JR, Hadji P , Holen I et al (2010) . Cancer Treatment Reviews, 36(8), 615-620.
  • Stresing V, Deux B, Benzaid I, Mathevet P, Ebetino H & Clézardin P (2010) . Bone, 46, S43-S43.
  • Gonin V, Bachelier R, Deux B, Contié S, Bonnelye E, Rabbitts P, Wu J & Clézardin P (2010) . Bone, 46, S37-S37.
  • Arkko S, Mönkkönen J, Auriola S, Dronda IR, Benzaid I, Stresing V, Clezardin P & Mönkkönen H (2010) . Bone, 46, S40-S41.
  • David M, Wannecq E, Jansen S, Deux B, Ribeiro J, Serre C-M, Grès S, Bendriss-Vermare N, Bollen M, Saulnier-Blache J-S , Clézardin P et al (2010) . Bone, 46, S41-S41.
  • Benzaid I, Mönkkönen H, Stresing V, Bonnelye E, Green J, Mönkkönen J & Clézardin P (2010) . Bone, 46, S43-S43.
  • Clezardin P & Massaia M (2010) . Current Pharmaceutical Design, 16(27), 3007-3014.
  • Clezardin P (2010) . Current Pharmaceutical Design, 16(11), 1260-1261.
  • Daubiné F, Cortial D, Ladam G, Atmani H, Haïkel Y, Voegel J-C, Clézardin P & Benkirane-Jessel N (2009) . Biomaterials, 30(31), 6367-6373.
  • Contié S, Voorzanger-Rousselot N, Litvin J, Bonnet N, Ferrari S, Conway SJ, Clézardin P & Garnero P (2009) . Bone, 44, S270-S270.
  • Clézardin P (2009) . IBMS BoneKEy, 6(6), 210-217.
  • Serre CM, Ribeiro J, Bonnelye E, Clézardin P & Peyruchaud O (2009) . Bone, 44, S135-S135.
  • Voorzanger-Rousselot N, Goehrig D, Facon T, Clézardin P & Garnero P (2009) . British Journal of Haematology, 145(2), 264-266.
  • Boucharaba A, Guillet B, Menaa F, Hneino M, van Wijnen AJ, Clezardin P & Peyruchaud O (2009) Bioactive Lipids Lysophosphatidic Acid and Sphingosine 1-Phosphate Mediate Breast Cancer Cell Biological Functions Through Distinct Mechanisms (vol 18, pg 173, 2009). ONCOLOGY RESEARCH, 18(7), 357-357.
  • Clézardin P (2009) . Oncologie, 11(1), 10-15.
  • Clezardin P (2009) . Current Cancer Drug Targets, 9(7), 801-806.
  • Boucharaba A, Guillet B, Menaa F, Hneino M, van Wijnen AJ, Clézardin P & Peyruchaud O (2009) . Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics, 18(4), 173-184.
  • Fournier PGJ, Daubiné F, Lundy MW, Rogers MJ, Ebetino FH & Clézardin P (2008) . Cancer Research, 68(21), 8945-8953.
  • Kischel P, Guillonneau F, Dumont B, Bellahcène A, Stresing V, Clézardin P, Pauw EAD & Castronovo V (2008) . Neoplasia, 10(9), 1014-IN11.
  • Le Gall C, Bonnelye E & Clézardin P (2008) . Current Opinion in Supportive and Palliative Care, 2(3), 218-222.
  • Ottewell PD, Deux B, Monkkonen H, Cross S, Coleman RE, Clezardin P & Holen I (2008) . Clinical Cancer Research, 14(14), 4658-4666.
  • Clézardin P (2008) . Revue du Rhumatisme, 75(4), 327-331.
  • Garcia T, Jackson A, Bachelier R, Clément-Lacroix P, Baron R, Clézardin P & Pujuguet P (2008) . Clinical & Experimental Metastasis, 25(1), 33-42.
  • Stresing V, Daubiné F, Benzaid I, Mönkkönen H & Clézardin P (2007) . Cancer Letters, 257(1), 16-35.
  • Clézardin P (2007) . Bone, 41(5), 901-902.
  • Voorzanger-Rousselot N, Goehrig D, Journe F, Doriath V, Body JJ, Clézardin P & Garnero P (2007) . British Journal of Cancer, 97(7), 964-970.
  • Le Gall C, Bellahcène A, Bonnelye E, Gasser JA, Castronovo V, Green J, Zimmermann J & Clézardin P (2007) . Cancer Research, 67(20), 9894-9902.
  • Buijs JT, Henriquez NV, van Overveld PGM, van der Horst G, Que I, Schwaninger R, Rentsch C, ten Dijke P, Cleton-Jansen A-M, Driouch K , Lidereau R et al (2007) . Cancer Research, 67(18), 8742-8751.
  • Zhao Y, Bachelier R, Treilleux I, Pujuguet P, Peyruchaud O, Baron R, Clément-Lacroix P & Clézardin P (2007) . Cancer Research, 67(12), 5821-5830.
  • Body J-J, Coleman R, Clezardin P, Ripamonti C, Rizzoli R & Aapro M (2007) . European Journal of Cancer, 43(5), 852-858.
  • Baum O, Hlushchuk R, Forster A, Greiner R, Clézardin P, Zhao Y, Djonov V & Gruber G (2007) Increased invasive potential and up-regulation of MMP-2 in MDA-MB-231 breast cancer cells expressing the β3 integrin subunit. International Journal of Oncology, 30(2), 325-332.
  • Daubine F, Le Gall C, Gasser J, Green J & Clezardin P (2007) . JNCI Journal of the National Cancer Institute, 99(4), 322-330.
  • Henriquez NV, van Overveld PGM, Que I, Buijs JT, Bachelier R, Kaijzel EL, Löwik CWGM, Clezardin P & van der Pluijm G (2007) . Clinical & Experimental Metastasis, 24(8), 699-705.
  • Clezardin P & Teti A (2007) . Clinical & Experimental Metastasis, 24(8), 599-608.
  • Bellahcène A, Bachelier R, Detry C, Lidereau R, Clézardin P & Castronovo V (2007) . Breast Cancer Research and Treatment, 101(2), 135-148.
  • Boucharaba A, Serre C-M, Guglielmi J, Bordet J-C, Clezardin P & Peyruchaud O (2006) . Proceedings of the National Academy of Sciences, 103(25), 9643-9648.
  • Bellahcene A, Bachelier , Detry C, Lidereau R, Clezardin P & Castronovo V (2006) . European Journal of Cancer Supplements, 4(2), 163-163.
  • Staquet M-J, Couble M-L, Roméas A, Connolly M, Magloire H, Hynes RO, Clezardin P, Bleicher F & Farges J-C (2006) . Cell and Tissue Research, 323(3), 457-463.
  • Fontana A, Filleur S, Guglielmi J, Frappart L, Bruno-Bossio G, Boissier S, Cabon F & Clézardin P (2005) . International Journal of Cancer, 116(5), 686-691.
  • Clézardin P, Ebetino FH & Fournier PGJ (2005) . Cancer Research, 65(12), 4971-4974.
  • Peyruchaud O, Boucharaba A, Saulnier-Blache J-S & Clézardin P (2005) . é𳦾Ա/Գ, 21(4), 353-355.
  • Colombel M, Filleur S, Fournier P, Merle C, Guglielmi J, Courtin A, Degeorges A, Serre CM, Bouvier R, Clézardin P & Cabon F (2005) Androgens repress the expression of the angiogenesis inhibitor thrombospondin-1 in normal and neoplastic prostate.. Cancer Res, 65(1), 300-308.
  • CLEZARDIN P (2005) . Cancer Treatment Reviews, 31, 1-8.
  • Boucharaba A, Serre C-M, Grès S, Saulnier-Blache JS, Bordet J-C, Guglielmi J, Clézardin P & Peyruchaud O (2004) . Journal of Clinical Investigation, 114(12), 1714-1725.
  • Peyruchaud O, Serre C-M, NicAmhlaoibh R, Sveigaard C & Clézardin P (2004) [Does tumor angiogenesis play a role in bone metastatic process?].. Rev Med Suisse Romande, 124(2), 83-84.
  • Peyruchaud O, Serre C-M, NicAmhlaoibh R, Fournier P & Clézardin P (2003) . Journal of Biological Chemistry, 278(46), 45826-45832.
  • Filleur S, Courtin A, Ait-Si-Ali S, Guglielmi J, Merle C, Harel-Bellan A, Clézardin P & Cabon F (2003) SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth.. Cancer Res, 63(14), 3919-3922.
  • Colombel M, Fournier P, Bouvier R, Cabon F & Clezardin P (2003) . European Urology Supplements, 2(1), 82-82.
  • Clezardin P, Fournier P, Boissier S & Peyruchaud O (2003) . Current Medicinal Chemistry, 10(2), 173-180.
  • Clézardin P (2003) Biphosphonates and bone metastases of solid tumors: Therapeutic significance beyond osteolytic activity. Progres en Urologie, 13(2 SUPPL. 1), 28-35.
  • Green JR & Clézardin P (2002) . American Journal of Clinical Oncology, 25, S3-S9.
  • Cl[eacute]zardin P (2002) . Seminars in Oncology, 29(6 Suppl 21), 33-42.
  • Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M & Clézardin P (2002) Bisphosphonates inhibit angiogenesis in Vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Research, 62(22), 6538-6544.
  • Clézardin P (2002) . Revue du Rhumatisme, 69(10-11), 997-1001.
  • Pecheur I, Peyruchaud O, Serre C, Guglielmi J, Voland C, Bourre F, Margue C, Cohen‐Solal M, Buffet A, Kieffer N & CléZardin P (2002) . The FASEB Journal, 16(10), 1266-1268.
  • Colombel M, Fournier P, Boissier S, Martin X & Clezardin P (2002) . European Urology Supplements, 1(1), 52-52.
  • Filleur S (2001) . Genes & Development, 15(11), 1373-1382.
  • Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, Colombel M, Delmas P, Delaissé JM & Clézardin P (2000) Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases.. Cancer Res, 60(11), 2949-2954.
  • Clézardin P (2000) [Bone hyperresorption in bone metastases].. Presse Med, 29(9), 487-491.
  • Clézardin P, Gligorov J & Delmas P (2000) . Revue du Rhumatisme, 67(1), 28-36.
  • Clézardin P, Gligorov J & Delmas P (2000) Mechanisms of action of bisphosphonates on tumor cells and prospects for use in the treatment of malignant osteolysis.. Joint Bone Spine, 67(1), 22-29.
  • Merle B, Durussel L, Delmas PD & Cl�zardin P (1999) . Journal of Cellular Biochemistry, 75(3), 538-546.
  • Bah I, David MP, Konan PG, Clezardin P & Colombel M (1999) Modulation of prostatic angiogenesis. Oncologie, 1(7), 428-432.
  • Magnetto S, Boissier S, Delmas PD & Clezardin P (1999) . International Journal of Cancer, 83(2), 263-269.
  • Clézardin P, Bruno-Bossio G, Fontana A, Serre CM, Magnetto S & Frappart L (1999) [Thrombospondins, tumor angiogenesis and breast cancer].. Pathol Biol (Paris), 47(4), 368-374.
  • Magnetto S, Bruno-Bossio G, Voland C, Lecerf J, Lawler J, Delmas P, Silverstein R & Clezardin P (1998) . Cell Biochem Funct, 16(3), 211-221.
  • Clezardin P (1998) . Cellular and Molecular Life Sciences (CMLS), 54(6), 541-548.
  • Merle B, Malaval L, Lawler J, Delmas P & Clezardin P (1997) . Journal of Cellular Biochemistry, 67(1), 75-83.
  • Boissier S, Magnetto S, Frappart L, Cuzin B, Ebetino FH, Delmas PD & Clezardin P (1997) Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices.. Cancer Res, 57(18), 3890-3894.
  • CLEZARDIN P, LAWLER J, AMIRAL J, QUENTIN G & DELMAS P (1997) . Biochemical Journal, 321(3), 819-827.
  • Bertin N, Clezardin P, Kubiak R & Frappart L (1997) Thrombospondin-1 and -2 messenger RNA expression in normal, benign, and neoplastic human breast tissues: correlation with prognostic factors, tumor angiogenesis, and fibroblastic desmoplasia.. Cancer Res, 57(3), 396-399.
  • Boissier S, Cuzin B, Delmas PD & Clezardin P (1995) . Bone, 17(6), 599-599.
  • Serre CM, Boivin G, Clezardin P, Delmas PD & Frappart L (1995) . Virchows Archiv, 427(4).
  • Pechoux C, Clezardin P, Dante R, Serre CM, Clerget M, Bertin N, Lawler J, Delmas PD, Vauzelle JL & Frappart L (1994) . Differentiation, 57(2), 133-141.
  • Péchoux C, Clezardin P, Dante R, Serre CM, Clerget M, Bertin N, Lawler J, Delmas PD, Vauzelle JL & Frappart L (1994) . Differentiation, 57(2), 133-133.
  • Abbadia Z, Amiral J, Trzeciak M-C, Delmas PD & Clezardin P (1993) . FEBS Letters, 335(2), 161-166.
  • Clezardin P, Drouin J, Morel-Kopp MC, Hanss M, Kehrel B, Serre CM, Kaplan C & Delmas PD (1993) Role of Platelet Membrane Glycoproteins Ib/IX and Ilb/IIIa, and of Platelet a-Granule Proteins in Platelet Aggregation Induced by Human Osteosarcoma Cells. Cancer Research, 53(19), 4695-4700.
  • Abbadia Z, Clezardin P, Serre C-M, Amiral J & Delmas PD (1993) . FEBS Letters, 329(3), 341-346.
  • Clezardin P, Clerget M & Delmas PD (1993) Expression of Thrombospondin (TSP1) and Its Receptors (CD36 and CD51) in Normal, Hyperplastic, and Neoplastic Human Breast. Cancer Research, 53(6), 1421-1430.
  • Clézardin P & Delmas PD (1993) [Role of osteoclasts in the physiopathological mechanisms of malignant osteolysis].. Bull Cancer, 80(10 Suppl), 11-15.
  • Breton-Gorius J, Clezardin P, Guichard J, Debili N, Malaval L, Vainchenker W, Cramer EM & Delmas PD (1992) . Blood, 79(4), 936-941.
  • Breton-Gorius J, Clezardin P, Guichard J, Debili N, Malaval L, Vainchenker W, Cramer EM & Delmas PD (1992) . Blood, 79(4), 936-941.
  • Clezardin P, Serre CM, Trzeciak MC, Drouin J & Delmas PD (1991) Thrombospondin binds to the surface of human osteosarcoma cells and mediates platelet-osteosarcoma cell interaction.. Cancer Res, 51(10), 2621-2627.
  • Vuillard L, Clezardin P & Miller A (1991) . Biochemical Journal, 275(1), 263-266.
  • CLEZARDIN P, JOUISHOMME H, CHAVASSIEUX P & MARIE PJ (1989) . European Journal of Biochemistry, 181(3), 721-726.
  • McGregor JL, Catimel B, Parmentier S, Clezardin P, Dechavanne M & Leung LL (1989) Rapid purification and partial characterization of human platelet glycoprotein IIIb. Interaction with thrombospondin and its role in platelet aggregation.. J Biol Chem, 264(1), 501-506.
  • CLEZARDIN P, MALAVAL L, EHRENSPERGER A-S, DELMAS PD, DECHAVANNE M & MCGREGOR JL (1988) . European Journal of Biochemistry, 175(2), 275-284.
  • Clezardin P, Bourdillon M-C, Hunter NR & McGregor JL (1988) . FEBS Letters, 228(2), 215-218.
  • Clezardin P (1987) . äDzٲDZDz, 07(06), 172-182.
  • Clezardin P, Hunter N, Lawler J, Dawes J & McGregor J (1987) . Seminars in Thrombosis and Hemostasis, 13(03), 261-275.
  • Dawes J, Clezardin P & Pratt D (1987) . Seminars in Thrombosis and Hemostasis, 13(03), 378-384.
  • CLEZARDIN P, HUNTER NR, LAWLER JW, PRATT DA, McGREGOR JL, PEPPER DS & DAWES J (1986) . European Journal of Biochemistry, 159(3), 569-579.
  • Clezardin P, Hunter NR, MacGregor IR, MacGregor JL, Pepper DS & Dawes J (1986) . Journal of Chromatography A, 358, 209-218.
  • Clezardin P, Bougro G & McGregor JL (1986) . Journal of Chromatography A, 354, 425-433.
  • Clezardin P, Hunter NR, McGregor JL, Pepper DS & Dawes J (1986) . FEBS Letters, 196(1), 49-53.
  • CLEZARDIN P, McGREGOR JL, LYON M, CLEMETSON KJ & HUPPERT J (1986) . European Journal of Biochemistry, 154(1), 95-102.
  • Clezardin P, McGregor JL, Dechavanne M & Clemetson KJ (1985) . British Journal of Haematology, 60(2), 331-344.
  • McGregor JL, Clezardin P, Manach M & Dechavanne M (1985) . Journal of Chromatography A, 326, 179-190.
  • McGREGOR JL, CLEZARDIN P, JAMES E, McGREGOR L, DECHAVANNE M & CLEMETSON KJ (1985) . European Journal of Biochemistry, 148(1), 97-106.
  • Clezardin P, McGregor JL, Manach M, Boukerche H & Dechevanne M (1985) . Journal of Chromatography A, 319, 67-77.
  • Clezardin P, McGregor JL, Manach M, Robert F, Dechavanne M & Clemetson KJ (1984) . Journal of Chromatography A, 296, 249-256.
  • Dawes J, Clemetson KJ, Gogstad GO, McGregor J, Clezardin P, Prowse CV & Pepper DS (1983) . Thrombosis Research, 29(6), 569-581.
  • McGregor JL, Clemetson KJ, James E, Clezardin P, Dechavanne M & Lüscher EF (1982) . Biochimica et Biophysica Acta (BBA) - Biomembranes, 689(3), 513-522.
  • Puppo M, Jaafar M, Diaz J-J, Marcel V & Clézardin P () . Cancers, 15(1), 242-242.
  • Bellanger A, Le DT, Vendrell J, Wierinckx A, Pongor LS, Solassol J, Lachuer J, Clezardin P, Győrffy B & Cohen PA () . Frontiers in Oncology, 11.
  • Donini CF, El Helou M, Wierinckx A, Győrffy B, Aires S, Escande A, Croze S, Clezardin P, Lachuer J, Diab-Assaf M , Ghayad SE et al () . Frontiers in Oncology, 10.
  • Clement-Demange L, Le PF, Eckel B, Geraci S, Diaz-Latoud C & Clezardin P () . Bone Abstracts.
  • Pantano F, Croset M, Driouch K, Bonnelye E, Bednarz-Knoll N, Hong S-S, Iuliani M, Fioramonti M, Santini D, Tonini G , Pantel K et al () . Bone Abstracts.
  • Confavreux CB, Chambard L, Ollier E, Brevet M, Duboeuf F, Rousseau J-C, Pialat J-B, Wegrzyn J, Tescaru A, Szulc P , Carlier M-C et al () . Bone Abstracts.
  • Reynaud C, Ferreras L, Brevet M & Clezardin P () . Bone Abstracts.
  • David M, Sahay D, Mege F, Descotes F, Leblanc R, Ribeiro J, Clézardin P & Peyruchaud O () . PLoS ONE, 9(5), e97771-e97771.
  • Fradet A, Sorel H, Depalle B, Serre CM, Farlay D, Turtoi A, Bellahcene A, Follet H, Castronovo V, Clézardin P & Bonnelye E () . PLoS ONE, 8(9), e75092-e75092.
  • Santini D, Schiavon G, Vincenzi B, Gaeta L, Pantano F, Russo A, Ortega C, Porta C, Galluzzo S, Armento G , La Verde N et al () . PLoS ONE, 6(4), e19234-e19234.
  • David M, Wannecq E, Descotes F, Jansen S, Deux B, Ribeiro J, Serre C-M, Grès S, Bendriss-Vermare N, Bollen M , Saez S et al () . PLoS ONE, 5(3), e9741-e9741.
  • Saltel F, Chabadel A, Zhao Y, Lafage-Proust M-H, Clézardin P, Jurdic P & Bonnelye E () . Journal of Bone and Mineral Research, 21(12), 1913-1923.
  • Peyruchaud O, Winding B, Pécheur I, Serre C-M, Delmas P & Clézardin P () . Journal of Bone and Mineral Research, 16(11), 2027-2034.
  • Voland C, Serre C-M, Delmas P & Clézardin P () . Journal of Bone and Mineral Research, 15(2), 361-368.
  • Clezardin P, Malaval L, Trzeciak M-C, Guichard J, Lecompte T, Morel M-C, Dechavanne M, Breton-Gorius J, Delmas PD & Kaplan C () . Journal of Bone and Mineral Research, 6(10), 1059-1070.
  • Hinz N, Baranowsky A, Horn M, Kriegs M, Sibbertsen F, Smit DJ, Clezardin P, Lange T, Schinke T & Jücker M () . Cells, 10(2), 430-430.
  • Confavreux CB, Follet H, Mitton D, Pialat JB & Clézardin P () . Cancers, 13(22), 5711-5711.

Book chapters

  • Puppo M, Valluru MK & Clézardin P (2022) , Bone Cancer (pp. 457-469). Elsevier
  • Delpuech B, Nicolle S, Confavreux CB, Bouazza L, Clezardin P, Mitton D & Follet H (2020) , Advanced Structured Materials (pp. 17-34). Springer International Publishing
  • Coleman RE, Croucher PI, Padhani AR, Clézardin P, Chow E, Fallon M, Guise T, Colangeli S, Capanna R & Costa L (2020) Springer Science and Business Media LLC
  • Clézardin P, Sousa S, Croset M, Pantano F & Confavreux C (2020) , Encyclopedia of Bone Biology (pp. 403-420). Elsevier
  • Bernard M, Di Mauro P, Reynaud C, Diaz-Latoud C & Clézardin P (2019) , Encyclopedia of Endocrine Diseases (pp. 304-309). Elsevier
  • Croset M & Clézardin P (2015) , Bone Cancer (pp. 479-489). Elsevier
  • Clézardin P (2010) , Bone Cancer (pp. 41-45). Elsevier
  • Ando K, Arslandemir C, Bell WC, Berdal A, Berthold D, Bhat BM, Bhat RA, Bhattacharyya S, Billiard J, Blanchard F , Bodine PVN et al (2010) , Bone Cancer (pp. xi-xv). Elsevier
  • BOUKERCHE H, McGREGOR JL, McGREGOR L, CLEZARDIN P, CLEMETSON KJ, DECHAVANNE M & BROCHIER J (1985) , Protides of the Biological Fluids (pp. 821-824). Elsevier
  • CLEZARDIN P, McGREGOR JL, LYON M, SHAO HZ, BOUKERCHE H, CLEMETSON KJ, DECHAVANNE M & HUPPERT J (1985) , Protides of the Biological Fluids (pp. 815-820). Elsevier
  • Clezardin P, McGregor JL, James E, Dechavanne M & Clemetson KJ (1984) , Proceedings of the Second Symposium Lyon, France, June 27–30, 1983 (pp. 601-604). De Gruyter
  • Clezardin P, McGregor JL, James E, Dechavanne M & Clemetson KJ (1984) , Proceedings of the Second Symposium Lyon, France, June 27–30, 1983 (pp. 601-604). De Gruyter
  • Coleman RE & Clézardin P () , Textbook of Bone Metastases (pp. 345-350). John Wiley & Sons, Ltd

Conference proceedings

  • Das S, Gabrion A, Six I, Boudot C, Kamel S, Clezardin P, Brazier M & Mentaverri R (2019) . Tumor Biology
  • Das S, Gabrion A, Six I, Boudot C, Kamel S, Clezardin P, Brazier M & Mentaverri R (2019) . Tumor Biology
  • Vargas G, Bouchet M, Kan C, Benetollo C, Croset M, Mazel M, Cayrefourcq L, Vacher S, Pantano F, Driouch K , Bieche I et al (2018) ERRa in primary breast tumours promotes tumour cell dissemination to bone by regulating RANK. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 33 (pp 72-72)
  • Croset M, Pantano F, Kan C, Bonnelye E, Descotes F, Alix-Panabières C, Lecellier C, Bachelier R, Allioli N, Hong SS , Bartkowiak K et al (2018) . Molecular and Cellular Biology / Genetics
  • Sousa S, Gineyts E, Geraci S, Croset M & Clézardin P (2018) . Tumor Biology
  • Pantano F, Croset M, Driouch K, Iuliani M, Fioramonti M, Santini D, Tonini G, Bednarz-Knoll N, Pantel K & Clezardin P (2016) . ANNALS OF ONCOLOGY, Vol. 27
  • Gineyts E, Bonnet N, Bertholon C, Pagnon-Minot A, Borel O, Hartmann D, Chapurlat RD, Ferrari S, Garnero P, Clezardin P & Rousseau J-C (2016) ELISA MEASUREMENT OF CIRCULATING PERIOSTIN IN ANIMAL MODELS OF BONE LOSS OR BONE FORMATION AND IDENTIFICATION OF CIRCULATING AND TISSUE-SPECIFIC ASSOCIATED FORMS OF PERIOSTIN. OSTEOPOROSIS INTERNATIONAL, Vol. 27 (pp S207-S207)
  • Mathevet P, Magaud L & Clézardin P (2016) . Poster Session Abstracts
  • Reynaud C, Ferreras L & Clezardin P (2014) THE HIF-1 TARGET LYSYL OXIDASE PROMOTES SURVIVAL AND OUTGROWTH OF COLON CANCER CELLS IN THE BONE MARROW ENABLING BONE METASTASIS FORMATION. ANTICANCER RESEARCH, Vol. 34(10) (pp 6134-6134)
  • Sahay D, Leblanc R, Ribeiro J, Clézardin P & Peyruchaud O (2014) . Molecular and Cellular Biology
  • Bouchet M, Fradet A, Delliaux C, Bouazza L, Pantano F, Leroy X, Bellahcene A, Castonovo V, Clezardin PAR, Duterque-Coquillaud M & Bonnelye E (2014) ERRalpha, a pro-Bone metastatic factor : Implication in metastatic Niche and prostate Cancer Stem Cells phenotype.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 29 (pp S13-S13)
  • Clement-Demange L, Eckel B, Gonin V, Goehrig D, Diaz-Latoud C & Clezardin PAR (2014) Roundabout receptors mediate breast cancer bone metastasis formation and progression.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 29 (pp S65-S66)
  • Pantano F, Croset M, Driouch K, Bonnelye E, Iuliani M, Fioramonti M, Santini D, Tonini G & Clezardin PAR (2014) Integrin Alpha5beta1 is a Potential Therapeutic Target to Treat Experimental Breast Cancer Bone Metastasis.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 29 (pp S65-S65)
  • Pantano F, Croset M, Driouch K, Santini D, Tonini G & Clézardin P (2013) . Poster Session Abstracts
  • Brevet M, Confavreux CB, Pialat J-B, Devouassoux-Shisheboran M, Isaac S, Rousseau J-C, Bringuier P-P, Clezardin P, Thivolet-Bejui F & Girard N (2013) MUTATIONAL PROFILING OF SYNCHRONOUS BONE METASTASES FROM LUNG ADENOCARCINOMA: FEASIBILITY AND RESULTS IN A PROSPECTIVE COHORT OF 46 PATIENTS (POUMOS STUDY). JOURNAL OF THORACIC ONCOLOGY, Vol. 8 (pp S796-S796)
  • Croset M, Goehrig D, Ansieau S, Puisieux A & Clezardin PAR (2013) Ectopic expression of twist-1 in breast cancer cells promotes bone metastasis formation. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 28
  • Fradet A, Bellahcene A, Castronovo V, Clezardin PAR & Bonnelye E (2013) Function of ERRa in Mediating Mixed Metastatic Bone Lesion from Prostate Cancer Cells: Implication of Endothelin 1 and Wnt/periostin pathway. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 28
  • Diaz-Latoud C, Gonin V, Eckel B, Bachelier R, Deux B, Bonnelye E & Clezardin P (2011) Role of axon guidance receptor Robo-1 in training and development of bone metastases of breast cancer. BULLETIN DU CANCER, Vol. 98 (pp S27-S28)
  • Reynaud C, Pez F, Dayan F, Clezardin P, Sommer P & Pouyssegur J (2011) The HIF-1-inducible Lysyl Oxidase activates HIF-1 via the Akt pathway in a positive regulation loop and synergizes with HIF-1 in promoting tumor cell. BULLETIN DU CANCER, Vol. 98 (pp S9-S10)
  • Clezardin P (2011) PATHOPHYSIOLOGY OF TUMORAL BONE DISEASE. OSTEOPOROSIS INTERNATIONAL, Vol. 22 (pp 6-7)
  • Croset M, Bachelier R, Allioli N, Song S-S, Agami R & Clezardin P (2011) Targeting breast cancer osteomimetic genes by microRNAs-30 decreases the formation of metastatic osteolytic lesions in mice. BULLETIN DU CANCER, Vol. 98 (pp S29-S30)
  • Benzaid I, Monkkonen H, Stresing V, Bonnelye E, Green J, Monkkonen J, Touraine J & Clezardin P (2010) . BONE, Vol. 47 (pp S266-S267)
  • Bachelier R, Gonin V, Goehrig D, Deux B, Van der Pluijm G & Clezardin P (2010) . BONE, Vol. 47 (pp S322-S323)
  • Fradet A, Sorel H, Deux B, Clezardin P & Bonnelye E (2010) . BONE, Vol. 47 (pp S289-S289)
  • Gonin V, Bachelier R, Deux B, Contie S, Bonnelye E, Rabbitts P, Wu J & Clezardin P (2010) . BONE, Vol. 47 (pp S273-S273)
  • Lowik CWG, Contie S, Voorzanger-Rousselot N, Litvin J, Clezardin P & Garnero P (2010) . BONE, Vol. 47 (pp S328-S329)
  • Stresing V, Deux B, Mathevet P, Ebetino FH & Clezardin P (2010) . BONE, Vol. 47 (pp S322-S322)
  • David M, Wannecq E, Jansen S, Deux B, Ribeiro J, Serre C-M, Grès S, Bendriss-Vermare N, Bollen M, Saulnier-Blache J-S , Clézardin P et al (2010) . Tumor Biology
  • Ricci E, Bourrelly E, Mege LF, Martin X, Clezardin P & Colombel M (2010) . European Urology Supplements, Vol. 9(2) (pp 221-221)
  • Voorzanger-Rousselot N, Goehrig D, Clezardin P, Facon T & Garnero P (2008) Platelets Contribute to Circulating Levels of Dickkopf-1 (Dkk-1): Clinical Implications in Multiple Myeloma.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 23 (pp S297-S297)
  • Boucharaba A, Guillet B, Menaa F, Heino M, VanWijnen A, Clezardin P & Peyruchaud O (2008) Lysophospholipids LPA and S1P cooperate to mediate the growth and osteolytic bone metastasis formation of breast cancer. CANCER RESEARCH, Vol. 68(9)
  • David M, Deux B, Serre CM, Bendriss-Vermare N, Caux C, Saulnier-Blache JS, Clezardin P & Peyruchaud O (2008) Autotaxin controls the metastatic progression of breast cancer cells. BULLETIN DU CANCER, Vol. 95 (pp S91-S92)
  • Monkkonen H, Benzaid I, Stresing V, Green J, Monkkonen J, Touraine JL & Clezardin P (2008) . Bone, Vol. 42 (pp S102-S103)
  • Bachelier R, Gonin V, Goehrig D, Deux B & Clézardin P (2008) . Cancer Treatment Reviews, Vol. 34 (pp 41-41)
  • Monkkonen H, Benzaid I, Stresing V, Green J, Monkkonen J, Touraine J-L & Clezardin P (2008) . Cancer Treatment Reviews, Vol. 34 (pp 37-37)
  • Clezardin P (2008) New physiopathological pathways of bone metastases. CALCIFIED TISSUE INTERNATIONAL, Vol. 82 (pp S24-S24)
  • Daubiné F, Fournier P, Ebetino H & Clezardin P (2008) . Cancer Treatment Reviews, Vol. 34 (pp 42-42)
  • David M, Wannecq E, Grès S, Deux B, Serre CM, Bendriss-Vermare N, Caux C, Saulnier-Blache J-S, Clézardin P & Peyruchaud O (2008) . Cancer Treatment Reviews, Vol. 34 (pp 20-21)
  • Clezardin P (2008) Cathepsin K inhibitors for treating cancer-induced bone disease. CLINICAL & EXPERIMENTAL METASTASIS, Vol. 25 (pp 15-15)
  • Ottewell PD, Deux B, Monkkonen H, Cross SS, Coleman RE, Clezardin P & Holen I (2007) Differential effects of doxorubicin and zoledronic acid on intra-osseous vs extra-osseous breast tumour growth in vivo.. BREAST CANCER RESEARCH AND TREATMENT, Vol. 106 (pp S39-S39)
  • Body JJ, Coleman R, Clezardin P, Ripamonti C, Rizzoli R & Aapro M (2007) . European Journal of Cancer Supplements, Vol. 5(4) (pp 174-174)
  • Ottewell PD, Deux B, Monkkonen H, Coleman RE, Clezardin P & Holen I (2007) Differential effect of doxorubicin and zoledronic acid on intra-osseous vs extra osseous breast tumour growth in vivo. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 22(7) (pp 1111-1111)
  • Boucharaba A, Menaa F, Clezardin P & Peyruchaud O (2007) Role of lysophosphatidic acid (LPA) and LPA1 receptor in the treatment of bone metastases in breast cancer. BULLETIN DU CANCER, Vol. 94(6) (pp 560-561)
  • Buijs J, Henriquez N, van Overveld P, van der Horsy G, Que I, Schwaninger R, Rentsch C, ten Dijke P, Cleton A, Lidereau R , Bachelier R et al (2007) Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer. BONE, Vol. 40(6) (pp S145-S145)
  • Saltel F, Chabadel A, Zhao Y, Lafage-Proust M, Clezardin P, Jurdic P & Bonnelye E (2006) Transmigration, a new property of mature osteoclasts.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 21 (pp S161-S161)
  • Peyruchaud O, Boucharaba A, Serre C-M & Clezardin P (2006) The type 1 lysophosphatidic acid receptor (LPA1): identification of a new therapeutic target for patients with bone metastases. CANCER RESEARCH, Vol. 66(8)
  • Fournier P, Daubiné F, Lundy MW, Ebetino FH & Clézardin P (2006) . Bone, Vol. 38(3) (pp 45-45)
  • Le Gall C, Guglielmi J, Gasser J, Zimmermann J & Clézardin P (2006) . Bone, Vol. 38(3) (pp 55-56)
  • Guglielmi J, Daubiné F, Gasser J, Green J & Clézardin P (2006) . Bone, Vol. 38(3) (pp 44-45)
  • (2006) Transcriptome analysis reveals an osteomimetic phenotype for human bone metastatic breast cancer cells. CALCIFIED TISSUE INTERNATIONAL, Vol. 78 (pp S85-S86)
  • (2006) Dickkopf-1 (Dkk-1) is involved in the development of breast cancer osteolytic lesions. CALCIFIED TISSUE INTERNATIONAL, Vol. 78 (pp S27-S27)
  • Clezardin P & Ctement-Lacroix P (2006) Prevention of breast cancer bone metastasis by an integrin alpha V beta 3 antagonist. CANCER TREATMENT REVIEWS, Vol. 32 (pp S18-S18)
  • Le Gall C, Gasser J, Bonnelye E, Zimmermann J & Clezardin P (2006) A cathepsin K inhibitor inhibits the progression of breast cancer bone metastases. CANCER TREATMENT REVIEWS, Vol. 32 (pp S16-S16)
  • Daubine F, Fournier P, Boucher P & Clezardin P (2006) Integrin alpha V beta 3 confers tumor cells a higher sensitivity to the pro-apoptotic effect of the aminobisphosphonate zoledronate in vitro. CANCER TREATMENT REVIEWS, Vol. 32 (pp S45-S46)
  • Bachelier R, Gonin V, Goehrig D, Confavreux C & Clezardin P (2006) Effects of thrombospondin-1 overexpression and VEGF silencing on bone metastasis formation. CANCER TREATMENT REVIEWS, Vol. 32 (pp S41-S41)
  • Voorzanger-Rousselot N, Goehrig D, Clezardin P & Garnero P (2006) Serum levels of Dickkopf-1 (Dkk-1) are increased in women with breast cancer and bone metastases. CANCER TREATMENT REVIEWS, Vol. 32 (pp S38-S38)
  • Boucharaba A, Clezardin P & Peyruchaud O (2006) The type 1 lysophosphatidic acid receptor is a pivotal factor for early and late events for bone metastasis formation in breast cancer. CANCER TREATMENT REVIEWS, Vol. 32 (pp S30-S30)
  • Fournier PG, Ebetino FH, Castronovo V & Clezardin P (2005) Use of bisphosphonate analogs of risedronate to elucidate antiangiogenic mechanisms of bisphosphonates in vivo. BONE, Vol. 36 (pp S219-S219)
  • Fournier PG, Ebetino FH, Castronovo V & Clezardin P (2005) Use of bisphosphonate analogs of risedronate to elucidate antiangiogenic mechanisms of bisphosphonates in vivo. CANCER TREATMENT REVIEWS, Vol. 31 (pp S23-S24)
  • Guglielmi J, Pecheur I, Pujuguet P, Minet D, Baron R, Clement-Lacroix P & Clezardin P (2005) A novel integrin antagonist: Evaluation in bone growth tumor models. CANCER TREATMENT REVIEWS, Vol. 31 (pp S16-S16)
  • Fournier PGJ, Ebetino FH, Lundy MW & Clezardin P (2005) Use of analogs of risedronate to elucidate antitumor mechanisms of bisphosphonates in vivo. CANCER TREATMENT REVIEWS, Vol. 31 (pp S36-S37)
  • Zhao Y, Fournier P, Serre CM, Boucharaba A, Guglielmi J, Peyruchaud O & Clezardin P (2005) Integrin alpha v beta 3 is critical for human breast cancer bone metastasis. CANCER TREATMENT REVIEWS, Vol. 31 (pp S26-S26)
  • Boucharaba A, Serre C, Blache JS, Bordet J, Clezardin P & Peyruchaud O (2005) LPA: A new local factor acting on breast cancer bone metastasis. CANCER TREATMENT REVIEWS, Vol. 31 (pp S27-S27)
  • Fournier P, Ebetino FH, Bellahcene A, Castronovo V & Clezardin P (2005) Antibody to rank ligand - Overview of RANK ligand. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 20 (pp P23-P24)
  • Fournier P, Ebetino FH, Bellahcene A, Castronovo V & Clezardin P (2005) Use of bisphosphonate analogs of risedronate to elucidate antiangiogenic mechanisms of bisphosphonates in vivo. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 20 (pp P24-P24)
  • Zhao Y, Boucharaba A, Fournier P & Clezardin P (2005) Integrin alpha V beta 3 is critical for human breast cancer bone metastasis. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 20 (pp P16-P17)
  • Jackson A, Pujuguet P, Clement-Lacroix P, Baron R, Clezardin P & Garcia T (2005) Genome profiling aiming at identifying "bone metastasis signatures". JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 20 (pp P36-P36)
  • Bellahcene A, Bachelier R, Detry C, Clezardin P & Castronovo V (2005) Transcriptome analysis reveals an osteomimetic phenotype for human breast cancer cells that selectively target the skeleton. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 20 (pp P32-P32)
  • Boucharaba A, Serre C, Blache JS, Bordet J, Guglielmi J, Clezardin P & Peyruchaud O (2004) Lysophosphatidic acid: A new link between breast cancer and bone metastasis.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 19 (pp S25-S25)
  • Guglielmi J, Pecheur I, Pujuguet P, Minet D, Baron R, Clement-Lacroix P & Clezardin P (2004) A nonpeptide integrin avb3 antagonist inhibits bone metastasis formation. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 19 (pp S66-S66)
  • Fournier PG, Lundy MW, Ebetino RH & Clezardin P (2004) Use of bisphosphonate analogs of risedronate to elucidate antitumor mechanisms of bisphosphonates in vivo.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 19 (pp S25-S25)
  • Fournier P, Serre CM, Colombel M, Ebetino FH & Clezardin P (2004) The bisphosphonate risedronate inhibits angiogenesis and tumor growth in vivo. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 19(9) (pp 1599-1599)
  • Clezardin P (2004) Cell adhesion and bone metastasis. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 19(9) (pp 1561-1562)
  • Lundy MW, Ebetino FH & Clezardin P (2004) NE-10790, a phosphonocarboxylate analogue of the bisphosphonate risedronate, exhibits direct antitumor activity in vivo. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 19(6) (pp 1033-1033)
  • Fournier PG, Lundy MW, Ebetino FH & Clezardin P (2004) NE-10790, A PHOSPHONOCARBOXYLATE ANALOGUE OF THE BISPHOSPHONATE RISEDRONATE, EXHIBITS DIRECT ANTITUMOR ACTIVITY IN IN VIVO. CALCIFIED TISSUE INTERNATIONAL, Vol. 74 (pp S43-S44)
  • Fournier PG, Lundy MW, Ebetino FH & Clezardin P (2004) NE-10790, a phosphonocarboxylate analogue of the bisphosphonate risedronate, exhibits direct antitumor activity in vivo. BONE, Vol. 34 (pp S56-S57)
  • Fournier P, Boissier S, Serre C, Colombel M, Ebetino FH & Clezardin PAR (2003) The bisphosphonate risedronate inhibits angiogenesis and tumor growth in vivo.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 18 (pp S113-S113)
  • Colombel MC, Fournier P, Bouvier R & Clezardin P (2003) Androgens repress the expression of thrombospondin-1, an inhibitor of angiogenesis, in the rat prostate and in hormone-responsive human prostate cancer. JOURNAL OF UROLOGY, Vol. 169(4) (pp 84-84)
  • Pecheur I, Peyruchaud O, Fournier P, Sarre CM, Bourre F, Delmas PD, Kieffer N & Clezardin P (2002) Integrin alpha v beta 3 plays an essential role in the homing of tumor cells in bone.. BONE, Vol. 30(3) (pp 43S-43S)
  • Fournier P, Peyruchaud O, Frappart L, Serre CM, Boissier S, Delmas P & Clezardin P (2002) Effects of bisphosphonates zoledronic acid and risedronate on the growth of a human breast carcinoma cell line in vivo. BONE, Vol. 30(3) (pp 40S-40S)
  • Boissier S, Colombel M, Delmas P, Cabon F & Clezardin P (2002) Zoledronic acid inhibits in vivo experimental angiogenesis. BONE, Vol. 30(3) (pp 38S-38S)
  • Pecheur L, David M, Schaffer-Reckinger S, Delmas PD, Kieffer N & Clezardin PAR (2000) Ectopic expression of integrin alpha v beta 3 confers tumor cells a high propensity to metastasize to bone.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 15 (pp S177-S177)
  • Clézardin P (2000) Effects of bisphosphonates on different steps of the metastatic cascade leading to bone metastasis formation. Medecine et Hygiene, Vol. 58(2305 SUPPL.)
  • Voland C, Kehrel B, Grahe H, Amiral J, Lawler J & Clezardin P (1997) Identification of specific sequences within thrombospondin-1 involved in the formation of irreversible platelet macroaggregates. THROMBOSIS AND HAEMOSTASIS (pp P1385-P1385)
  • Merle B, Choi HU, Amiral J, Rosenberg L, Lawler J, Delmas PD & Clezardin P (1996) Decorin inhibits cell adhesion by binding to a specific cell adhesive site of thrombospondin.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 11 (pp M460-M460)
  • Boissier S, Lozano S, Cuzin B, Delmas PD & Clezardin P (1996) Bisphosphonates inhibit tumor cell attachment to unmineralized and mineralized bone extracellular matrices.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 11 (pp P229-P229)
  • CLEZARDIN P, LOZANO S, LAWLER J, SILVERSTEIN R, LECERF J & DELMAS P (1995) MOLECULAR MECHANISMS OF ATTACHMENT OF CD36-TRANSFECTED CELLS TO THROMBOSPONDIN-1. MOLECULAR BIOLOGY OF THE CELL, Vol. 6 (pp 267-267)
  • CLEZARDIN P, DROUIN J, KAPLAN C, HANSS M, KEHREL B, SERRE CM, MORELKOPP MC & DELMAS P (1993) MECHANISMS OF PLATELET-OSTEOSARCOMA CELL-INTERACTIONS. THROMBOSIS AND HAEMOSTASIS, Vol. 69(6) (pp 573-573)
  • CLEZARDIN P, FRAPPART L, CLERGET M, PECHOUX C & DELMAS PD (1993) EXPRESSION OF THROMBOSPONDIN (TSP1) AND ITS RECEPTORS (CD36, CD51) IN NORMAL, HYPERPLASTIC AND NEOPLASTIC HUMAN BREAST. JOURNAL OF CELLULAR BIOCHEMISTRY (pp 159-159)
  • FRAPPART L, CLEZARDIN P, DANTE R, SERRE CM, CLERGET M & PECHOUX C (1993) ORIGIN AND ROLE OF THROMBOSPONDIN IN THE EARLY DEVELOPMENT OF THE HUMAN MAMMARY-GLAND. JOURNAL OF CELLULAR BIOCHEMISTRY (pp 160-160)
  • HOTT M, CLEZARDIN P & MARIE PJ (1992) THROMBOSPONDIN INDUCES THE PROLIFERATION OF RAT CALVARIA OSTEOBLASTIC CELLS. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 7 (pp S213-S213)
  • ABBADIA Z, CLEZARDIN P, SERRE C, MAILLARD C & DELMAS PD (1992) THROMBOSPONDIN MEDIATES PROLIFERATION OF HUMAN OSTEOBLASTIC CELLS INDUCED BY THROMBIN. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 7 (pp S223-S223)
  • CLEZARDIN P, SERRE CM, TRZECIAK MC, DELMAS P & DROUIN J (1991) THROMBOSPONDIN BINDS TO THE SURFACE OF HUMAN OSTEOSARCOMA CELLS AND MEDIATES PLATELET-OSTEOSARCOMA CELL-INTERACTION. THROMBOSIS AND HAEMOSTASIS, Vol. 65(6) (pp 1055-1055)
  • DROUIN J, MCLEISH W, SUTHERLAND M & CLEZARDIN P (1991) PSEUDO-GRAY PLATELET SYNDROME - MULTIPLE PLATELET ABNORMALITIES AND NORMAL HEMOSTASIS. THROMBOSIS AND HAEMOSTASIS, Vol. 65(6) (pp 1105-1105)
  • CLEZARDIN P, ALFARO E, GRANGE J, DESGRANGES C, KAPLAN C, DELMAS P & DECHAVANNE M (1991) THROMBOSPONDIN BINDING BY HUMAN OSTEOSARCOMA CELLS - RELATIONSHIP TO PLATELET-AGGREGATING ACTIVITY OF OSTEOSARCOMA CELLS. PLATELET IMMUNOLOGY : FUNDAMENTAL AND CLINICAL ASPECTS, Vol. 206 (pp 195-207)
  • CLEZARDIN P, JOUISHOMME H, CHAVASSIEUX P & MARIE PJ (1989) THROMBOSPONDIN AND CELL-ADHESION. THROMBOSIS AND HAEMOSTASIS, Vol. 62(1) (pp 592-592)
  • CLEZARDIN P, MALAVAL L, DELMAS PD & KAPLAN C (1989) OSTEONECTIN DEFICIENCY IN PLATELETS ISOLATED FROM A PATIENT WITH THE GRAY PLATELET SYNDROME. THROMBOSIS AND HAEMOSTASIS, Vol. 62(1) (pp 420-420)
  • CLEZARDIN P, MALAVAL L, DELMAS PD & KAPLAN C (1989) A POLYCLONAL ANTIBODY TO OSTEONECTIN INHIBITS COLLAGEN-INDUCED PLATELET-AGGREGATION AND CELL-SURFACE EXPRESSION OF ENDOGENOUS THROMBOSPONDIN. THROMBOSIS AND HAEMOSTASIS, Vol. 62(1) (pp 195-195)
  • MCGREGOR J, CATIMEL B, PARAMENTIER S, CLEZARDIN P, DECHAVANNE M & LEUNG L (1988) RAPID PURIFICATION AND PARTIAL CHARACTERIZATION OF HUMAN-PLATELET GLYCOPROTEIN IIIB. CLINICAL RESEARCH, Vol. 36(3) (pp A567-A567)
  • CLEZARDIN P & MCGREGOR JL (1987) STRUCTURAL AND FUNCTIONAL COMPARISON OF THROMBOSPONDIN FROM PLATELETS, ENDOTHELIAL-CELLS AND FIBROBLASTS. THROMBOSIS AND HAEMOSTASIS, Vol. 58(1) (pp 278-278)
  • Clezardin P & McGregor JL (1987) . XIth International Congress on Thrombosis and Haemostasis, 6 July 1987 - 10 July 1987.
  • CLEZARDIN P & DAWES J (1986) STRUCTURAL AND IMMUNOLOGICAL COMPARISON OF THROMBOSPONDIN FROM PLATELETS AND COLOSTRUM. THROMBOSIS RESEARCH (pp 55-55)
  • BOUKERCHE H, MCGREGOR JL, MCGREGOR L, CLEZARDIN P, DECHAVANNE M, CLEMETSON KJ & BROCHIER J (1985) CHARACTERIZATION OF AN ANTI-THROMBOSPONDIN MURINE MONOCLONAL-ANTIBODY (P8) THAT INHIBITS HUMAN-BLOOD PLATELET FUNCTIONS. THROMBOSIS AND HAEMOSTASIS, Vol. 54(1) (pp 218-218)
  • ROBERT F, MCGREGOR JL, CLEZARDIN P, SAYEGH A, DECHAVANNE M & CHATAING B (1985) STUDY ON THE RELEASE OF THROMBOSPONDINE DURING PLATELET CONSERVATION - DOSAGE BY MEANS OF THE ELISA METHOD, WITH A MONOCLONAL-ANTIBODY. NOUVELLE REVUE FRANCAISE D HEMATOLOGIE, Vol. 27(2) (pp 117-117)
  • CLEZARDIN P, MCGREGOR JL, LYON M, BOUKERCHE H, DECHAVANNE M & HUPPERT J (1985) CHARACTERIZATION OF MONOCLONAL-ANTIBODIES WHICH AFFECT HUMAN-PLATELET THROMBOSPONDIN HEMAGGLUTINATION ACTIVITY. THROMBOSIS AND HAEMOSTASIS, Vol. 54(1) (pp 249-249)
  • MCGREGOR JL, SICARD B, CLEZARDIN P, JAMES E, CLEMETSON KJ & DECHAVANNE M (1984) MEMBRANEOUS PROTEINS AND GLYCOPROTEINS OF ENDOTHELIAL-CELLS FROM UMBILICAL CORDS. NOUVELLE REVUE FRANCAISE D HEMATOLOGIE, Vol. 26(6) (pp 417-417)
  • CLEZARDIN P, MCGREGOR JL, DECHAVANNE M & CLEMETSON KJ (1983) PLATELET MEMBRANE GLYCOPROTEIN ABNORMALITIES IN PATIENTS WITH MYELOPROLIFERATIVE DISORDERS, ACUTE-LEUKEMIA AND SECONDARY THROMBOCYTOSIS. THROMBOSIS AND HAEMOSTASIS, Vol. 50(1) (pp 218-218)
  • BENDOUMA M, MCGREGOR JL, CLEZARDIN P, DECHAVANNE M, AGUERCIF M & CLEMETSON KJ (1983) PROTEINS AND GLYCOPROTEINS OF NEONATAL PLATELETS. THROMBOSIS AND HAEMOSTASIS, Vol. 50(1) (pp 213-213)
  • CLEZARDIN P, MCGREGOR JL, MANACH M, DECHAVANNE M & CLEMETSON KJ (1983) PURIFICATION OF THROMBOSPONDIN, FIBRONECTIN AND FIBRINOGEN BY FAST PROTEIN LIQUID-CHROMATOGRAPHY. THROMBOSIS AND HAEMOSTASIS, Vol. 50(1) (pp 16-16)
  • MCGREGOR JL, CLEZARDIN P, JAMES E, MCGREGOR L, DECHAVANNE M & CLEMETSON KJ (1983) IDENTIFICATION AND CHARACTERIZATION OF FRAGMENTS OF MAJOR MEMBRANE-GLYCOPROTEINS REMAINING ON PLATELETS AFTER CHYMOTRYPSIN TREATMENT. THROMBOSIS AND HAEMOSTASIS, Vol. 50(1) (pp 187-187)
  • Clezardin P, McGregor L, McGregor JL, Clemetson KJ & Dechavanne M (1983) . European Heart Journal, Vol. 4(suppl B) (pp 5-5)
  • MCGREGOR JL, SICARD B, JAMES E, CLEZARDIN P, DECHAVANNE M & CLEMETSON KJ (1983) MEMBRANE-PROTEINS AND GLYCOPROTEINS OF ENDOTHELIAL-CELLS ISOLATED FROM HUMAN UMBILICAL CORDS. THROMBOSIS AND HAEMOSTASIS, Vol. 50(1) (pp 396-396)
  • Clezardin P, McGregor JL, Clemetson KJ, Dechavanne M & Lüscher EF (1981) . Oral Presentations, 13 July 1981 - 17 July 1981.
  • McGregor JL, Clemetson KJ, James E, Clezardin P, Dechavanne M & Lüscher EF (1981) . Oral Presentations, 13 July 1981 - 17 July 1981.
  • MCGREGOR JL, CLEMETSON KJ, JAMES E, CAPITANIO A, DECHAVANNE M & LUSCHER EF (1981) ADDITIONAL GLYCOPROTEIN DEFECTS IN GLANZMANN THROMBASTHENIA PLATELETS. THROMBOSIS AND HAEMOSTASIS, Vol. 46(1) (pp 22-22)
  • CLEZARDIN P, MCGREGOR JL, CLEMETSON KJ, DECHAVANNE M & LUSCHER EF (1981) FURTHER CHARACTERIZATION OF PLATELET MEMBRANE-GLYCOPROTEINS. THROMBOSIS AND HAEMOSTASIS, Vol. 46(1) (pp 108-108)
  • MCGREGOR JL, CLEMETSON KJ, JAMES E, CLEZARDIN P, DECHAVANNE M & LUSCHER EF (1981) TRYPTIC PEPTIDE MAPS OF THE MAJOR HUMAN-BLOOD PLATELET MEMBRANE-GLYCOPROTEINS, IIA, IIA, IIB, IIIA, IIIB AND IIIC. THROMBOSIS AND HAEMOSTASIS, Vol. 46(1) (pp 22-22)

Preprints

  • Iamshanova O, Gordienko D, Folcher A, Bokhobza A, Shapovalov G, Mariot P, Allart L, Desruelles E, Spriet C, Diez R , Oullier T et al () , Cold Spring Harbor Laboratory.
Teaching interests

I have supervised a total of 18 PhD students (16 as main supervisor and 2 as co-supervisor) and 9 postdocs.

I am currently module leader of the UE « Metastasis, Migration and EMT » for the Master in Oncology at the University Claude Bernard Lyon-1, Lyon, France.

Professional activities and memberships

I am/was engaged, as academic partner or coordinator, in several research projects/programmes funded by the French National Agency for Cancer (INCa) and INSERM, as well as European projects within the framework of FP6 and FP7, and H2020 research programmes [MetaBre (partner; 2004-2007), PROMET (partner; 2006-2010), BONE-NET (coordinator; 2011-2014), miROMeS (coordinator; 2016-2017)]. In this respect, I received a European Star Award (Paris, France, 2015) as coordinator of the Marie Curie ITN project BONE-NET.

Board of Directors member of the Laboratory of Excellence « DEVweCAN » funded by the French National Research Agency (ANR) (2011-present).

President of the Cancer & Bone Society (CABS; 2009-2010).

Board of Directors member of national and international learned societies (2004-2018) [CABS, International Bone and Mineral Society (IBMS), ARTP (French Prostate Cancer Society), and GEMO ((French Study Group of Bone Metastasis)].

Member of American Association for Cancer Research (AACR), American Society for Bone and Mineral Research (ASBMR), Cancer & Bone Society (CABS), and GEMO.